课题基金 / 基金详情

Identification of the ligands for KLRG1, an inhibitory receptor expressed on NK cells.

Identification of the ligands for KLRG1, an inhibitory receptor expressed on NK cells.
KLRG1 配体的鉴定,KLRG1 是 NK 细胞上表达的抑制性受体。
批准号:
15590057
负责人:
MATSUMOTO Naoki
金额:
$2.37万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2003
资助国家:
日本
项目状态:
已结题
起止时间:
2003 至 2004

项目摘要

项目成果

MATSUMOTO Naoki的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Bodies of the metazoan organisms are protected by the immune system. The immune system of vertebrates consists of acquired and innate immunity. Natural killer (NK) cells play pivotal roles in innate immunity especially against cancer cells and intracellular pathogens. NK cell recognition of targets involves NK cell receptors with opposing functions: inhibitory receptors and activating receptors. Balance of signals from these receptors decides activation of NK cells. Most of the known ligands for the inhibitory NK cell receptors are MHC class I molecules, which are considered as markers of self. However, NK cell recognition of targets is not solely depend on MHC class I. Indeed, NK cells express inhibitory receptors of which ligands are unidentified, which include KLRG1. KLRG1 is a lectin-like inhibitory receptor expressed on subsets of NK and T cells. Expression of KLRG1 is also regulated by infection. In the present study, our group identified three classical cadherins, which contribute to cell-cell adhesion through homotypic interaction, as ligands for KLRG1. We also showed that ligation of KLRG1 by E-cadherin inhibit NK cell ctyotoxocity. Because the classical cadherins that KLRG1 recognizes are distributed ubiquitously among the body, KLRG1 may contribute to the termination of immune response induced by infection. The notion that expression of E-cadherin is often lost or attenuated in malignant carcinoma raises a possibility that KLRG1-expressing NK cells may play a role in malignant tumor surveillance. The current study provides a new concept that cadherins contribute to regulation of immune response through recognition by KLRG1.
期刊论文(44)
专著(0)
科研奖励(0)
会议论文
Killer cell lectin-like receptor G1 binds three members of the classical cadherin family to inhibit NK cell cytotoxicity.
杀伤细胞凝集素样受体G1结合经典钙粘蛋白家族的三个成员,以抑制NK细胞细胞毒性。
DOI: 10.1084/jem.20051986
发表时间: 2006-02-20
期刊: The Journal of experimental medicine
影响因子: --
作者: [Ito M, Maruyama T, Saito N, Koganei S, Yamamoto K, Matsumoto N]
通讯作者: Matsumoto N
B-la cell origin of the murine B lymphoma line BCLIcharacterized by surface markers and bacterial reactivity of its surface IgM
鼠 B 淋巴瘤系 BCLI 的 B-la 细胞起源,其特征在于其表面 IgM 的表面标记和细菌反应性
DOI: --
发表时间: 2005
期刊: Immunol. Letters 98
影响因子: --
作者: [Kogamei S., Ito M., Yamamoto K., Matsumoto N.]
通讯作者: Matsumoto N.
Tajima K., Matsumoto N., Ohmori K., Wada H., Ito M., Suzuki K., Yamamoto K.: "Augmentation of NK cell-mediated cytotoxicity to tumor cells by inhibitory NK cell receptor blockers."International Immunology. 16. 385-393 (2004)
Tajima K.、Matsumoto N.、Ohmori K.、Wada H.、Ito M.、Suzuki K.、Yamamoto K.:“通过抑制性 NK 细胞受体阻断剂增强 NK 细胞介导的对肿瘤细胞的细胞毒性。”国际免疫学。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Annual Review 免疫2007
免疫学年度回顾 2007
DOI: --
发表时间: 2007
期刊:
影响因子: --
作者: [Saito M, Minegishi Y, Nonoyama S, and Karasuyama H., 鳥山 一]
通讯作者: 鳥山 一
17
    Development of efficient graph enumeration algorithms using graph generating theorems
    • 批准号:
      19K14583
    • 项目类别:
      Grant-in-Aid for Early-Career Scientists
    • 资助金额:
      $2.0万
    • 财政年份:
      2019
    • 负责人:
      MATSUMOTO Naoki
    • 依托单位:
    The relationship between landiolol and BCHE in the pediatric patients with congenital heart disease.
    The elucidation of myocardial protection effect and the development of myocardial protective strategy by beta-blocker, landiolol, in children.
    Function of the inhibitory receptor KLRG1 in innate and acquiredimmunity
    • 批准号:
      19590059
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.83万
    • 财政年份:
      2007
    • 负责人:
      MATSUMOTO Naoki
    • 依托单位:
    海外基金